Guidant Biotherapeutics
PUBLICATION
November 2025 Expansion of a Phase 1 Study of SON-1010 (IL12-FHAB) Adding Trabectedin in Soft Tissue Sarcoma: Trial in Progress
We are creating High-Value, Validated Assets with Navigated Delivery in Cancer Treatment
We believe that cancer patients deserve immune therapies that are not just powerful but precise. Guidant Biotherapeutics was founded to solve one of oncology's most persistent challenges: getting the right therapy to the right place, at the right dose, with minimal systemic harm.
ABOUT US
Our Technical Capabilities
Navigated Delivery Platform
We believe that cancer patients deserve therapies that are not just powerful but precise. Guidant Biotherapeutics was founded to solve one of oncology's most persistent challenges: getting the right therapy to the right place, at the right dose, with minimal systemic harm.
Guidant Biotherapeutics
Creating High-Value, Validated Assets with Navigated Delivery for Cancer Treatment
Our Clinical Programs
Our Pipeline
Our clinical-stage pipeline comprises dual-cytokine therapeutic candidates engineered on the FHAB platform, designed to address significant unmet medical needs across oncology and other indications. Our next generation Antibody Drug Conjugate (ADC) pipeline consists of a preclinical drug candidate validated by a proof of Concept candidate currently in a comprehensive animal study.
A IL-12 immunotherapy candidate designed to be best-in-class to turn 'cold' tumors 'hot’ while avoiding systemic immune-activation toxic effects. Currently in Phase 1 for advanced solid tumors and in combination with trabectedin (Yondelis®) for Soft-Tissue Sarcomas .Currently seeking partnership to move this forward into Phase 1B/IIA.
GDT-001 (IL12-FHAB)
Read More
Phase 1 | Solid Tumors
A first-in-class IL-12+IL-15 immunotherapy candidate delivering dual cytokine action directly to the tumor microenvironment.
GDT-002 (IL12-FHAB-IL15)
Read More
IND ready | Bladder Cancer and Solid Tumors
A first-in-class IL-12+IL-18 immunotherapy candidate with issued intellectual property delivering dual cytokine action directly to the tumor microenvironment.
GDT-003 (IL18-FHAB-IL12)
Read More
Preclinical | Solid Tumors
VIEW ALL
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Research and devlopment
Dec 2, 2025 • 9:17 AM EST
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Research and devlopment
Dec 2, 2025 • 9:17 AM EST
WHY PARTNER WITH US
Navigated Delivery(™) makes your therapeutics safer and more effective
Get In Touch
FHAB is a fully human, modular navigated-delivery(™) vehicle with well-established preclinical proof-of-concept, demonstrating up to 10x increase in serum half-life, improved tumor penetration, and significantly improved antitumor activity as a result of immune-modulating cytokines
Proprietary & Validated Navigated Delivery(™) Platform
Therapeutic candidates across immuno-oncology and precision oncology mechanisms of action shows the versatility of the platform, with ongoing Phase 1 studies.
Active Clinical Pipeline
Therapeutic candidates across immuno-oncology and precision oncology mechanisms of action shows the versatility of the platform, with ongoing Phase 1 studies.
Active Clinical Pipeline
LEADERSHIP
Guided by Expertise. Driven by Purpose.
The Guidant Biotherapeutics team combines deep technical expertise in cytokine biology with extensive experience in drug discovery and development.
Interested in GDT-001?
Guidant BioTherapeutics is actively engaging with potential partners and licensees interested in leveraging the strength of our proprietary FHAB technology platform.
Partner With Us
Partnerships Inquiry
Guided Cancer Therapeutics
Navigated delivery technology for safer and more effective cancer drugs
PUBLICATION
November 2025 Expansion of a Phase 1 Study of SON-1010 (IL12-FHAB) Adding Trabectedin in Soft Tissue Sarcoma: Trial in Progress
Guided Cancer Therapeutics
Navigated delivery technology for safer and more effective cancer drugs
PUBLICATION
November 2025 Expansion of a Phase 1 Study of SON-1010 (IL12-FHAB) Adding Trabectedin in Soft Tissue Sarcoma: Trial in Progress
We are creating High-Value, Validated Assets with Navigated Delivery in Cancer Treatment
We are creating High-Value, Validated Assets with Navigated Delivery in Cancer Treatment
We believe that cancer patients deserve immune therapies that are not just powerful but precise. Guidant Biotherapeutics was founded to solve one of oncology's most persistent challenges: getting the right therapy to the right place, at the right dose, with minimal systemic harm.
We believe that cancer patients deserve immune therapies that are not just powerful but precise. Guidant Biotherapeutics was founded to solve one of oncology's most persistent challenges: getting the right therapy to the right place, at the right dose, with minimal systemic harm.
ABOUT US
ABOUT US
Our Technical Capabilities
Our Technical Capabilities
We believe that cancer patients deserve therapies that are not just powerful but precise. Guidant Biotherapeutics was founded to solve one of oncology's most persistent challenges: getting the right therapy to the right place, at the right dose, with minimal systemic harm.
We believe that cancer patients deserve therapies that are not just powerful but precise. Guidant Biotherapeutics was founded to solve one of oncology's most persistent challenges: getting the right therapy to the right place, at the right dose, with minimal systemic harm.
Navigated Delivery Platform
Navigated Delivery Platform
Our Clinical Programs
Our Clinical Programs
Our Pipeline
Our Pipeline
Our clinical-stage pipeline comprises dual-cytokine therapeutic candidates engineered on the FHAB platform, designed to address significant unmet medical needs across oncology and other indications. Our next generation Antibody Drug Conjugate (ADC) pipeline consists of a preclinical drug candidate validated by a proof of Concept candidate currently in a comprehensive animal study.
Our clinical-stage pipeline comprises dual-cytokine therapeutic candidates engineered on the FHAB platform, designed to address significant unmet medical needs across oncology and other indications. Our next generation Antibody Drug Conjugate (ADC) pipeline consists of a preclinical drug candidate validated by a proof of Concept candidate currently in a comprehensive animal study.
View Full Pipeline
View Full Pipeline
A IL-12 immunotherapy candidate designed to be best-in-class to turn 'cold' tumors 'hot’ while avoiding systemic immune-activation toxic effects. Currently in Phase 1 for advanced solid tumors and in combination with trabectedin (Yondelis®) for Soft-Tissue Sarcomas .Currently seeking partnership to move this forward into Phase 1B/IIA.
A IL-12 immunotherapy candidate designed to be best-in-class to turn 'cold' tumors 'hot’ while avoiding systemic immune-activation toxic effects. Currently in Phase 1 for advanced solid tumors and in combination with trabectedin (Yondelis®) for Soft-Tissue Sarcomas .Currently seeking partnership to move this forward into Phase 1B/IIA.
GDT-001 (IL12-FHAB)
GDT-001 (IL12-FHAB)
Read More
Read More
Phase 1 | Solid Tumors
Phase 1 | Solid Tumors
A first-in-class IL-12+IL-15 immunotherapy candidate delivering dual cytokine action directly to the tumor microenvironment.
A first-in-class IL-12+IL-15 immunotherapy candidate delivering dual cytokine action directly to the tumor microenvironment.
GDT-002 (IL12-FHAB-IL15)
GDT-002 (IL12-FHAB-IL15)
Read More
Read More
IND ready | Bladder Cancer and Solid Tumors
IND ready | Bladder Cancer and Solid Tumors
A first-in-class IL-12+IL-18 immunotherapy candidate with issued intellectual property delivering dual cytokine action directly to the tumor microenvironment.
A first-in-class IL-12+IL-18 immunotherapy candidate with issued intellectual property delivering dual cytokine action directly to the tumor microenvironment.
GDT-003 (IL18-FHAB-IL12)
GDT-003 (IL18-FHAB-IL12)
Read More
Read More
Preclinical | Solid Tumors
Preclinical | Solid Tumors
VIEW ALL
VIEW ALL
Latest Research & Perspectives
Latest Research & Perspectives
Featured Insights
Featured Insights
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Research and devlopment
Research and devlopment
Dec 2, 2025 • 9:17 AM EST
Dec 2, 2025 • 9:17 AM EST
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Research and devlopment
Research and devlopment
Dec 2, 2025 • 9:17 AM EST
Dec 2, 2025 • 9:17 AM EST
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Research and devlopment
Research and devlopment
Dec 2, 2025 • 9:17 AM EST
Dec 2, 2025 • 9:17 AM EST
WHY PARTNER WITH US
WHY PARTNER WITH US
Navigated Delivery(™) makes your therapeutics safer and more effective
Navigated Delivery(™) makes your therapeutics safer and more effective
Get In Touch
Get In Touch
Therapeutic candidates across immuno-oncology and precision oncology mechanisms of action shows the versatility of the platform, with ongoing Phase 1 studies.
Therapeutic candidates across immuno-oncology and precision oncology mechanisms of action shows the versatility of the platform, with ongoing Phase 1 studies.
Active Clinical Pipeline
Active Clinical Pipeline
FHAB is a fully human, modular navigated-delivery(™) vehicle with well-established preclinical proof-of-concept, demonstrating up to 10x increase in serum half-life, improved tumor penetration, and significantly improved antitumor activity as a result of immune-modulating cytokines
FHAB is a fully human, modular navigated-delivery(™) vehicle with well-established preclinical proof-of-concept, demonstrating up to 10x increase in serum half-life, improved tumor penetration, and significantly improved antitumor activity as a result of immune-modulating cytokines
Proprietary & Validated Navigated Delivery(™) Platform
Proprietary & Validated Navigated Delivery(™) Platform
Our plug-and-play modular platform is compatible with many biologic drug classes, including interleukins, growth factors, cytokines, peptides, antibodies and vaccines, making it uniquely positioned for co-development and licensing.
Our plug-and-play modular platform is compatible with many biologic drug classes, including interleukins, growth factors, cytokines, peptides, antibodies and vaccines, making it uniquely positioned for co-development and licensing.
Built for Partnership
Built for Partnership
LEADERSHIP
LEADERSHIP
Guided by Expertise. Driven by Purpose.
Guided by Expertise. Driven by Purpose.
The Guidant Biotherapeutics team combines deep technical expertise in cytokine biology with extensive experience in drug discovery and development.
The Guidant Biotherapeutics team combines deep technical expertise in cytokine biology with extensive experience in drug discovery and development.
We welcome scientific inquiries, partnerships, and collaborations.
We welcome scientific inquiries, partnerships, and collaborations.
CONTACT US
CONTACT US
Email: contact@guidantbio.com
Phone: +1 (123) 456-7890
Email: contact@guidantbio.com
Phone: +1 (123) 456-7890
GET IN TOUCH
GET IN TOUCH
Guidant BioTherapeutics
Guidant BioTherapeutics
© 2026 Sonnet BioTherapeutics, Inc. All Rights Reserved.
© 2026 Sonnet BioTherapeutics, Inc. All Rights Reserved.
CONTACT
CONTACT
newsletter
newsletter